Glycoprotein Inhibitor for High-Risk Angioplasty Patients

The in-hospital incidence of death and combined death or reinfarction was 1.32% for patients who received the inhibitor early, compared to 1.53% who received it later.

"The data are significant because they suggest that earlier use of GP IIb-IIIa inhibitors, before the patient is taken to the catheterization lab, could directly improve patient outcomes,” said Matthew Roe, M.D., a principal investigator and the co-author of the study.

The data were collected from a national quality improvement initiative that retrospectively examined the treatment of high-risk chest pain in hospitals in the United States. The initiative was led by the Duke Clinical Research Institute (Durham, NC, USA; www.dcri.duke.edu). Although the results of the analysis are consistent with previous results of randomized clinical trials, the use of a GP IIb-IIIa inhibitor before catheterization remains low, the researchers noted.




Related Links:
Duke Clinical Research